RALES (see Randomized Aldactone Evaluation Study (RALES))

Raloxifene, 2277t

adverse effects of, 2281

for breast cancer, 2048

contraindications, 2281

dosing, 2280–2281

for osteoporosis, 2271

Raltegravir (RAL), 1581t

Ramelteon (Rozerem), 1768

for sleep, 1861

for treatment of insomnia, 1767t, 1768

Ramipril, 281–282, 281t, 609

in hypertension, 153t

Ramucirumab, 469t

for colon cancer, 2073, 2078

Randomized Aldactone Evaluation Study (RALES), 270

Ranibizumab, 1169

Ranitidine, 977, 1216t, 2163t

H2RA, 483t, 484

for preventing SRMB, 515t

RANKL inhibitors, 2096

Ranolazine, 120t, 211

for chronic stable angina, 214–215, 224, 224t

for myocardial ischemia, 223

Rapivab (see Peramivir)

Rasagiline, 1251t, 1255–1256, 1264

Rasburicase, 918

for AML, 2027

R-CHOP, 2042

Recombivax-HB, 1355

Rectal diazepam gel, 1294

Red clover, 942t

Reglan (see Metoclopramide)

Regorafenib, 470t

for colon cancer, 2073

Relaxation, 1024

Relenza (see Zanamivir)

Renagel (see Sevelamer)

RenAmin, 794t

Renvela (see Sevelamer)

Repaglinide, 1116, 1141

adverse effects of, 1113

contraindications and precautions of, 1113

dosage and clinical use of, 1117

drug interactions of, 1116

efficacy, 1116–1117

mechanism of action, 1113

pharmacokinetics of, 1113

Replens, 1037

Requip (see Ropinirole)

Reserpine, 157t

for hypertension, 159–160

Resorcinol, 1626

Restoril (see Temazepam)

Reteplase, 237

Retinoids, 827, 828

Revlimid (see Lenalidomide)

Rexulti (see Brexpiprazole)

Rhinocort Aqua (see Budesonide)

Rho

(D) immune globulin (RhoGAM), 999

Ribavirin (Virazole), 1649t

administration of, 1658

adverse effects, 1647t, 1658

for HCV, 1686

for HPS, 1659

for liver transplant recipients, 1686

for RSV, 1657–1658

for SARS, 1660

use in infants, 1657

for WNV infection, 1659–1660

Riboflavin, 173

Rifabutin

for MAC, 1619

for TB, 1616, 1617t

for tuberculosis, 1429t

Rifamate, 1429

Rifampin, 42, 53, 120t, 662, 942, 1370, 1376, 1720

acute renal failure and, 1437

adverse reactions with, 1437

and AIN, 645

for CNS infections, 1373t

discoloration of body fluids and, 1437

dosing of, 1338t

drug interactions with, 1437

flulike syndrome and, 1436–1437

for HAV, 1688

and hepatotoxicity, 1437

isoniazid and, 1437

for MAC, 1619

thrombocytopenia and, 1437

for tuberculosis, 1429t, 1433

Rifamycin, 942t, 1616

Rifapentine, 1429t

Rifater, 1429

Rifaximin (Xifaxan)

for global IBS symptoms, 536

hepatic encephalopathy, 553

for IBS with diarrhea, 536

and neomycin, 553

SBP and, 1474

for travelers’ diarrhea, 1461t

Rilonacept, 903

Rilpivirine (RPV), 1578t

Rimantadine (Flumadine), 1649t

adverse effects, 1647t

for influenza, 1655–1656

pharmacokinetics of, 1653t

Risedronate, 2277, 2277t, 2278

Risperdal (see Risperidone)

Risperidone (Risperdal), 1267, 1739, 1796t, 1797t, 1799t

fo

r

a

c

ut

e

ma

nia

,

1

8

4

5

t

fo

r

a

g

it

a

t

e

d

b

e

h

a

v

io

r

s

,

2

2

4

4

fo

r

A

S

D

,

1

8

5

6

,

1

8

6

0

fo

r

B

D

,

1

9

9

7

t

fo

r

b

ip

o

la

r

dis

o

r

d

e

r

,

1

8

4

9

t

fo

r

d

e

v

e

lop

me

nt

a

l

dis

o

r

d

e

r

s

,

1

8

5

7

fo

r

dy

s

lip

id

e

mia

,

1

8

0

3

fo

r

F

GA

s

,

1

8

0

3

fo

r

hyp

e

rp

r

o

la

c

t

in

e

mia

,

1

8

0

3

fo

r

O

C

D

,

1

7

5

7

fo

r

o

r

th

o

s

t

a

t

ic

hyp

o

t

e

n

s

io

n

,

1

8

0

1

fo

r

s

c

h

iz

op

hr

e

nia

,

1

7

8

8

,

1

7

9

0

,

1

7

9

2

,

1

7

9

2

t

,

1

7

9

3

,

1

7

9

3

t

R

i

t

o

n

av

i

r

(

R

T

V)

,

1

2

0

t

,

1

2

8

,

9

4

2

t

,

1

5

7

9

t

fo

r

S

A

R

S

,

1

6

6

0

R

i

t

u

x

a

n

(

s

e

e

R

i

t

u

x

i

m

a

b

)

R

i

t

u

x

i

m

a

b

,

4

6

9

t

,

6

4

1

,

8

8

1

,

8

8

3

,

8

9

6

t

,

8

9

7

,

8

9

8

–

8

9

9

,

1

9

8

2

t

,

2

0

4

0

t

fo

r

a

g

gr

e

s

s

iv

e

lymp

h

o

ma

s

,

2

0

4

2

fo

r

C

L

L

,

2

0

3

4

th

e

r

a

p

y

fo

r

LN

,

6

2

6

R

i

v

a

r

o

x

a

b

a

n

,

1

3

0

7

t

fo

r

mo

n

o

th

e

r

a

p

y

,

1

8

7

fo

r

p

r

e

v

e

nt

io

n

o

f

s

tr

o

ke

,

3

1

7

–

3

1

8

fo

r

s

tr

o

ke

p

r

e

v

e

nt

io

n

,

1

7

8

fo

r

w

a

r

fa

r

in

th

e

r

a

p

y

,

2

0

0

R

i

v

a

s

t

i

g

m

i

n

e

,

1

2

6

7

fo

r

A

lzh

e

ime

r

’

s

dis

e

a

s

e

,

2

2

3

8

fo

r

v

a

s

c

ula

r

d

e

me

nt

ia

,

2

2

4

2

R

i

z

a

t

ri

p

t

a

n

,

1

2

3

8

t

,

1

2

3

9

R

o

b

e

p

r

az

o

l

e

,

1

2

1

6

t

R

o

c

e

p

h

i

n

(

s

e

e

C

e

ft

ri

a

x

o

n

e

)

R

o

c

u

r

o

n

i

u

m

,

2

2

0

0

t

R

o

fe

c

o

x

i

b

,

5

0

0

,

7

0

7

R

o

fl

u

m

i

l

a

s

t

,

6

1

0

R

o

l

a

p

i

t

a

n

t

(

Va

r

u

b

i

)

,

4

7

2

t